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Introduction  
Intraperitoneal (IP) chemotherapy for advanced ovarian cancer remains a controversial 
treatment option, with conflicting views amongst gynaecological and medical oncologists 
worldwide. The benefit of intraperitoneal chemotherapy has been described in multiple trials, 
notably the pivotal randomised controlled trial by Armstrong et al. published in the New 
England Journal of Medicine. (1) Shortly following this in 2006, the National Cancer Institute 
(NCI) released a statement promoting the use of intraperitoneal chemotherapy in women with 
advanced ovarian cancer. (2) 
Despite this statement, the use of intraperitoneal chemotherapy has not been fully accepted or 
incorporated into current care. Concerns have been raised as to whether the findings from this 
trial truly have the weight to support intraperitoneal chemotherapy use as a standard of care. 
Toxicity associated with intraperitoneal administration is also a concern. Further questions 
have arisen regarding appropriate regimens, safe catheter administration, cost effectiveness and 
what patient subgroup are likely to have the best response.  
Here, we firstly outline the rationale behind intraperitoneal administration. Thereafter, we 
outline previous phase III trials comparing intraperitoneal versus intravenous chemotherapy, 
in terms of efficacy and toxicity. We explore dosing and regimens, catheter technology, cost 
effectiveness and outline what subtypes are most likely to respond. Finally, we express our 
views as to whether intraperitoneal chemotherapy is a viable, safe and effective treatment for 
patients with advanced ovarian malignancy.  
   
The rationale behind intraperitoneal chemotherapy 
Epithelial ovarian cancer accounts for the majority of ovarian tumours and often presents at an 
advanced stage (III/IV). (3) Patients generally initially respond well to cytoreduction and 
combined platinum-taxane chemotherapy. However, ultimately the majority of patients 
experience disease relapse with a poor overall survival. Low residual disease volume in the 
pelvis is a well-established good prognostic indicator. (4) 
In ovarian cancer, around 85% of patient have disease confined to the peritoneal cavity. (5) 
Cancer cells spread through this cavity, implanting on peritoneal surfaces and proliferating if 
the environment is neovascularly suitable. Spread may also be via the blood stream or 
lymphatic system, (6) although this is less common than in many other solid malignancies. 
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Given this natural history and the fact that the peritoneum is relatively accessible, 
intraperitoneal chemotherapy has been considered for decades. Pharmacokinetic advantages of 
intraperitoneal versus intravenous (IV) administration have been demonstrated in multiple 
studies. In intraperitoneal therapy, there are peak cytotoxic levels acting on peritoneal disease 
with an increased drug half-life, resulting in prolonged total drug exposure. (7) (8) Drugs 
administered into the peritoneal cavity are mainly taken up via the portal vein, and if they are 
hepatically metabolised may result in reduced systemic side effects. (8) 
Despite these described benefits, intraperitoneal therapy may result in uneven drug distribution 
due to adhesions. There is also poor penetration into deeper areas of disease. (7) (9) This was 
demonstrated in animal models, where no difference in cytotoxic concentration was noted in 
the centre of tumours (any greater than 1-2mm from the surface) when comparing intravenous 
and intraperitoneal administration. (8) Overall, the ideal intraperitoneal agent would not require 
liver activation, have a slow rate of peritoneal clearance with the ability to penetrate deeply 
into peritoneal tumours.(8)  Whether these described pharmacokinetic benefits can translate 
into improved clinical outcomes has been studied in phase III trials as outlined below.  
 
Phase III trials comparing intraperitoneal versus intravenous chemotherapy: efficacy & 
toxicities 
There have been many comparative trials of intraperitoneal versus intravenous chemotherapy 
in advanced ovarian malignancy. In the 1980s-1990s, multiple phase I and II trials identified 
intraperitoneal chemotherapy as a safe and feasible option, with unknown efficacy. (10-12)  
There have been three large phase III trials which show superiority of intraperitoneal 
chemotherapy compared to intravenous. These are the trials by Alberts et al. 1996 (GOG-104), 
(13) Markman et al. 2001 (GOG-114) (14) and the GOG-172 trial by Armstrong et al. in 2006. 
(1) These studies randomised patients following primary debulking surgery. In addition, the 
OV21/PETROC study randomised patients who responded to neoadjuvant chemotherapy to 
either intravenous or intraperitoneal post-debulking chemotherapy. (15) This trial had to 
undergo a change in its design due to recruitment issues resulting in less power to show a 
difference between the treatment arms and the results can be regarded as equivocal. A number 
of trials have also failed to demonstrate superiority of intraperitoneal chemotherapy as detailed 
below. With the exception of the GOG-252 study, (16) which was unique in that bevacizumab 
was also given to patients in both arms, these negative studies have been underpowered. 
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Data showing superiority of intraperitoneal compared to intravenous chemotherapy:  
Alberts et al. 1996 (GOG-104/SWOG-8501) conducted a phase III trial including 546 patients 
with stage III cancers (residual disease of less than 2cm). They received IV cyclophosphamide 
(600mg/m2) plus either, IP cisplatin (100mg/m2) or IV cisplatin (100mg/m2). (13) This was 
administered every 3 weeks, for a total of six cycles.  
The median overall survival was significantly increased in the intraperitoneal cisplatin group 
versus intravenous cisplatin (49 months [CI 42-56], versus 41 months [CI 34-47]). The risk of 
death was lower in those treated with intraperitoneal chemotherapy, compared to intravenous 
(hazard ratio: 0.76 CI [0.61-0.96], p = 0.02). Subgroup analysis revealed those with low 
residual disease (less than 0.5cm) were more likely to respond. Abdominal pain (grade 2 or 
above) was higher in the intraperitoneal group, but this responded well to simple analgesics. 
Adverse effects such as neutropenia, tinnitus, hearing loss and neuromuscular effects were 
more frequent in the intravenous group, as opposed to the intraperitoneal group.(13) 
This was the first trial to demonstrate superiority of intraperitoneal chemotherapy and the only 
variable factor was administration route (with the same chemotherapy and dosing in both 
arms). Despite these early promising results, the uptake of intraperitoneal chemotherapy did 
not significantly change amongst clinicians. This is likely because at the time of this publication 
there was emerging evidence to suggest the benefit of intravenous paclitaxel as combination 
first line therapy. The improved median survival when combining intravenous paclitaxel and 
intravenous platinum agents was significantly greater (14 months) than the substitution of 
intravenous cisplatin for intraperitoneal cisplatin (7 months). (13, 17) 
Markman et al. (GOG-114/SWOG-9227) conducted a randomised trial in 426 patients with 
residual disease less than 1cm. (14) One treatment arm received the new standard of care which 
was IV paclitaxel (135mg/m2) over 24 hours, followed by IV cisplatin (75mg/m2), every 3 
weeks for six cycles. The experimental treatment arm was IV carboplatin (AUC9) every 4 
weeks for 2 cycles, then IV paclitaxel (135mg/m2) over 24 hours, followed by IP cisplatin 
(100mg/m2) every 3 weeks, for 6 cycles (total 8 cycles of chemotherapy). The initial intensive 
carboplatin aimed to minimise residual disease volume prior to intraperitoneal therapy.  
Progression free survival (PFS) was significantly prolonged in the intraperitoneal group (28 
versus 22 months, relative risk 0.78; p=0.01). Effect on overall survival (OS) was borderline 
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significant (median 63 versus 52 months, relative risk 0.81; p=0.05). There was a greater 
incidence of grade 3 toxicities (haematological, gastrointestinal and metabolic) in the 
intraperitoneal group. Therefore, 18% of patients received two or fewer cycles of 
intraperitoneal therapy. The beneficial effects of the experimental arm may be related to the 
greater number of cycles (8 versus 6), intensive carboplatin or higher dose of cisplatin. (18) 
Given the minimal effect on survival and considerable toxicities, the authors concluded the 
experimental arm was not recommended for routine practice. (14)  
The GOG-172 phase III trial, published in 2006 included 429 patients with stage III ovarian 
cancer with residual disease of less than 1.0cm. (1) The experimental arm were given IV 
paclitaxel (135mg/m2), IP cisplatin (100mg/m2) and day 8 IP paclitaxel (60mg/m2). The 
control arm received IV paclitaxel (135mg/m2) and IV cisplatin (75mg/m2). Administration 
was three-weekly, for a total of six cycles. Primary outcomes were progression free survival 
(PFS) and overall survival (OS). Secondary endpoints included toxicities and quality of life.  
There was a significant benefit in PFS in the intraperitoneal group (23.8 versus 18.3 months, 
relative risk 0.80 [0.64-1.00] p=0.05). However, the benefit of intraperitoneal therapy on 
overall survival was notably more significant than PFS (65.6 versus 49.7 months, relative risk 
0.75 [0.58-0.97] p=0.03).(1) This overall survival benefit (15.9 months) was the greatest to 
date from a first line randomised controlled trial. (19) This survival benefit was present 
(although not statistically significant) on subgroup analysis in both those with residual and 
microscopic disease (relative risk 0.77 [0.57-1.04], 0.69 [0.41-1.17] respectively). (1)   
The side effects and toxicities in the intraperitoneal group were significantly higher. Only 42% 
in the intraperitoneal group received six cycles, versus 83% in the intravenous group. Despite 
this, the majority (90% intravenous, 83% intraperitoneal) received six courses of some 
chemotherapy. Catheter-related complications (n=40, 33%) and toxicity (n=31, 26%) 
accounted for the majority of reasons for discontinuation of intraperitoneal therapy. (1) 
Quality of life (QOL) was reported as poorer in the intraperitoneal group before cycle 4 and 3-
6 weeks following treatment completion. However, no difference in QOL was present one year 
after treatment completion. (1) Shortly following this publication, the National Cancer Institute 
released a statement promoting the use of intraperitoneal chemotherapy, as described below.   
The recently published OV21/PETROC study compared the use of intraperitoneal versus 
intravenous chemotherapy in 275 patients who had responded to neoadjuvant platinum based 
chemotherapy for stage IIB-IVA epithelial ovarian cancer and been successfully debulked to a 
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maximum residual disease of <1cm. The trial was designed so that the dose intensities were 
comparable between the intravenous and intraperitoneal arms. It started as a three-arm study 
comparing: paclitaxel 135mg/m2 IV and carboplatin AUC 5/6 IV day1 plus paclitaxel 
60mg/m2 IV day8 versus; paclitaxel 135 mg/m2 IV and cisplatin 75 mg/m2 IP day1 plus 
paclitaxel 60 mg/m2 IP day8 versus; paclitaxel 135 mg/m2 IV and carboplatin AUC 5/6 IP 
day1 plus paclitaxel 60 mg/m2 IP day8. After stage one of the study as the cisplatin IP arm had 
failed to show superiority, phase two proceeded as a direct comparison of the carboplatin IV 
versus IP arms. The primary endpoint was adjusted to 9-month progressive disease rate because 
of slow recruitment and lack of funding to proceed to the planned phase III recruitment of >800 
patients. Using this endpoint, there appeared to be an advantage for the IP arm with 24.5% of 
patients having progressed at 9 months compared to 38.6% of the control arm, although this 
did not reach conventional levels of statistical significance (p=0.065). Importantly, the IP 
carboplatin regime was well tolerated with no difference in quality of life or toxicity when 
compared to the intravenous arm. 
 
Data showing no survival benefit of intraperitoneal chemotherapy: 
Kirmani et al. 1994, compared IV cisplatin (100mg/m2) and IV cyclophosphamide 
(600mg/m2) (3 weekly, 6 cycles), versus IP cisplatin (200mg/m2) and IP etoposide 
(350mg/m2) (4 weekly, 6 cycles), in 62 patients with stage IIC-IV disease. There was no 
difference in survival or in toxicities. (20) 
Following the GOG-104 trial, a similar trial by Polyzos et al. (1999) analysed 90 patients with 
stage III disease. (21) They were randomised to either IV carboplatin (350mg/m2) plus IV 
cyclophosphamide (600mg/m2) (six cycles) or IP carboplatin (350mg/m2) plus IV 
cyclophosphamide (600mg/m2) (six cycles). Progression free survival was similar in both 
groups (19 months IV, 18 months IP), as was overall survival (25 months IV, 26 months IP). 
The intravenous group had higher rates of haematological toxicities. Authors concluded that 
intravenous and intraperitoneal carboplatin were equally effective, with less myelotoxicity with 
intraperitoneal administration. In comparison to GOG-104, this study was smaller and included 
variable residual disease. The findings suggested it was unlikely that patients with large 
residual disease benefit from intraperitoneal administration, compared to intravenous. This is 
consistent with findings from radiolabelled drug studies showing poor tumour penetration in 
larger tumours. (22) 
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Gadducci et al. 2000 analysed 113 patients with debulked stage II-IV ovarian tumours. (23) 
They were randomised to ipPEC; IP cisplatin (50mg/m2) plus IV epidoxuribicin (60mg/m2) 
and IV cyclophosphamide (600mg/m2), or ivPEC; IV cisplatin (50mg/m2) plus IV 
epidoxuribicin (60mg/m2) and IV cyclophosphamide (600mg/m2), given four weekly for 6 
cycles. Treatment protocol changed in 2 patients in the ivPEC and 20 in the ipPEC group. There 
was a slight, but not statistically significant, difference in median PFS (42 months ipPEC versus 
25 months ivPEC, p=0.13) and overall survival (67 months ipPEC and 51 month ivPEC, 
p=0.14). There was no significant difference in toxicities.(23) 
Yen et al. 2001, compared 132 patients with minimal residual disease (less than 1cm) following 
cytoreduction. (24) Participants were randomised to either IP cisplatin (100mg/m2) or IV 
cisplatin (50mg/m2), along with IV cyclophosphamide (500mg/m2) and adriamycin or 
epirubicin. No difference in overall survival was noted. Frequency of haematological toxic 
effects was significantly reduced in the intraperitoneal group.  
Although published in abstract form only to date, the GOG-252 study is important as it is the 
largest phase III study performed in the field and the only one to report results in the last decade. 
(16) This study enrolled 1560 participants with stage II-IV epithelial ovarian cancer in the first 
line post-operative setting. Patients were randomised to receive: IV carboplatin AUC6 three-
weekly plus IV paclitaxel 80mg/m2 weekly versus; IP carboplatin AUC6 three-weekly plus IV 
paclitaxel 80mg/m2 weekly versus; IV paclitaxel 135mg/m2 day1 plus IP cisplatin 75mg/m2 
day2 plus IP paclitaxel 80mg/m2 day8 as part of a three-weekly regime. All patients also 
received IV bevacizumab 15mg/kg three weekly from cycle 2 to 22. There was no significant 
difference in PFS (median 24.9 months in IV arm versus 27.3 months in the IP carboplatin arm 
and 26.0 months in the IP cisplatin arm). It has been suggested that including bevacizumab or 
weekly treatment in each arm may have negated the impact of intraperitoneal chemotherapy in 
this study. It is also of note that the dose of IP cisplatin (75mg/m2) used was less than the 
100mg/m2 used in all of the positive studies to date. 
Consolidation therapy:  
Piccart et al. 2003, uniquely analysed 153 patients with mainly stage III ovarian cancer who 
had achieved pathological complete remission following intravenous chemotherapy and 
cytoreduction. They were randomised to 4 cycles of intraperitoneal cisplatin (90mg/m2 every 
3 weeks) or observation. Following 8 years of follow up, the hazard ratios for PFS and OS were 
0.89 (95% CI: 0.59-1.33) and 0.82 (0.52-1.29). This suggested a slight treatment benefit but 
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not substantial enough to support a change in clinical practice. (25) Interestingly, a Cochrane 
review found no evidence to suggest intravenous maintenance chemotherapy improved 
survival, versus observation. Therefore, the lack of benefit in this trial is likely not solely related 
to route of administration. (26)  
 
 
National Cancer Institute Announcement: 
 
In 2006, following the GOG-172 trial, the National Cancer Institute (NCI) issued a statement. 
Following data analysis, they concluded intraperitoneal therapy was associated with an average 
21.6% reduction in risk of death (HR 0.79 [0.70=0.89]). This clinically translated to a 12 month 
increase in overall survival (based on expected median survival 4 years). Their announcement 
encouraged the use of intraperitoneal chemotherapy in women following optimal 
cytoreduction, stating “strong consideration should be given to a regimen with intraperitoneal 
cisplatin and a taxane, whether given by an IV only or IV plus IP”.  (2) Extensive adhesions 
was a relative contra-indication due to poor drug distribution. (7) They acknowledged the 
greatest survival benefit was observed with IP cisplatin 100mg/m2, though the optimal 
intraperitoneal regimen was unclear. Toxicities were acknowledged but felt to be short-term 
and treatable.  
Following this announcement, there was significant disagreement between clinicians 
worldwide. Gore et al. 2006 published a commentary outlining multiple reasons why they felt 
the GOG-172 trial did not support intraperitoneal chemotherapy as standard care. (27) They 
meticulously analysed study design, stated the benefit was statistically marginal, raised 
concerns as to whether it was truly intention to treat (14 patients not included in survival 
calculation), and questioned how patients lost to follow up would affect results. They 
questioned whether a minimal improvement in PFS with a notable improvement in overall 
survival, was due to treatments following relapse or the intraperitoneal chemotherapy itself. 
No data detailing patient treatment following relapse was available. Whether intraperitoneal 
chemotherapy changes tumour biology and affects response to subsequent therapies remains 
unknown. (8) The use of intravenous cisplatin as the GOG-172 control arm was also criticised. 
Though no statistical significance between intravenous cisplatin and intravenous carboplatin 
was demonstrated in the GOG-158 trial, there was a trend towards superiority of intravenous 
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carboplatin. (28) The improved outcome of the intraperitoneal treatment arm in GOG-172 was 
speculated to be heightened by using intravenous cisplatin, which is not the current standard of 
care. (5) Armstrong responded, justifying their study design, acknowledging toxicity concerns 
but overall continued to strongly support intraperitoneal chemotherapy. (29) Interestingly,  a 
Cochrane systematic review still identified a survival benefit when GOG-172 and GOG-114 
were removed from analysis. (9)  
Following the NCI announcement, the Society of Gynaecology Oncologists also released a 
supportive statement, but they reiterated intraperitoneal chemotherapy should only be for 
patients optimally debulked and initiated by clinicians with expertise in catheter technology. 
(30)  
 
Systematic Review: 
A Cochrane systematic review based on 8 clinical trials (2026 patients) identified a significant 
improvement in overall survival (HR 0.81, 95% CI: [0.72-0.90]) in those treated with 
intraperitoneal versus intravenous chemotherapy. A significant progression free survival 
benefit (HR 0.98, 95% CI: [0.70-0.86]) was also identified.(9) Data was homogenous with no 
significant difference between subgroups.  
The authors concluded that intraperitoneal chemotherapy provided a survival advantage, but 
with increasing toxicities. They identified the importance of an individualised approach to each 
patient and further investigation into optimal dosing and administration. (9) 
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Toxicities: 
Of the three positive trials, GOG-104 reported reduced toxicities in the intraperitoneal 
chemotherapy group. (13) However, both GOG-114 and GOG-172 reported increased 
toxicities, which resulted in a significant proportion not completing intended intraperitoneal 
cycles. (1) (14) In Cochrane review, those treated with intraperitoneal chemotherapy were more 
likely to suffer adverse effects, notably; pain, fever, infection, metabolic and gastrointestinal 
toxicities. The data was heterogeneous and analysis less reliable. (9) 
Adverse effects can be categorised into chemotherapy-related or catheter-related. There was 
insufficient data for the Cochrane review to analyse catheter-related complications. (9) GOG-
172 reported catheter-related complications in around 33% of patients. Catheter type and 
timing were not specified in study design. Thirty six percent of patients not completing 
assigned intraperitoneal therapy was due to catheter complications, mainly infection or failure. 
Interestingly, patients with previous left colonic or recto-sigmoidal resection were less likely 
to receive planned intraperitoneal chemotherapy due to complications. (1)  
The NCI recommended a semi-permanent subcutaneous venous access port connected to a 
single lumen venous catheter. Fenestrated catheter designs were discouraged, due to increased 
rates of bowel complications. (2) A retrospective study of 301patients analysed complications 
of subcutaneous catheters. Catheters were often placed at laparotomy (69.6%) and otherwise 
were inserted at laparoscopy (19.5%) or as a separate procedure (10.9%). Only 30 women 
(10%) experienced complications, notably infection and obstruction. Only 21 patients (7%) 
had to stop intraperitoneal chemotherapy early. No incidents of bowel perforation or 
obstruction occurred. Higher rates of malfunction and infection were noted if catheter 
placement was during laparotomy. Therefore, toxicity may be minimised by instead placing 
catheters at laparoscopy. (31)  
Haematological chemotherapy-related toxicities were higher in the intraperitoneal group in 
GOG-172 (leucopenia p <0.001, thrombocytopenia p 0.002). This resulted in delay or omission 
of day 8 chemotherapy. (1) Neurotoxicity was also significantly higher in the intraperitoneal 
group (p=0.001). This may be due to dosing, as opposed to administration. Alberts et al., who 
used the same intravenous and intraperitoneal dose of cisplatin, conversely showed decreased 
neurotoxicity in the intraperitoneal group. (13) Neurotoxicity is especially important as further 
analysis of GOG-172 showed these toxicities are not necessarily treatable or short lived. (32)  
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The reported high incidence of toxicities has resulted in reluctance to incorporate 
intraperitoneal therapy into standard care. Catheter-related toxicities may be significantly 
minimised with appropriate catheter training and timing of insertion. Chemotherapy-related 
toxicities may be minimised by altering regimens or dosing.  
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Regimens & Dosing:  
Many cytotoxic agents have been tested via the intraperitoneal route. Intraperitoneal cisplatin 
has been extensively investigated, at doses between 50mg/m2 to 200mg/m2. Cisplatin plasma 
levels are lower when the drug is administered into the peritoneum as opposed to intravenously, 
which may reduce systemic toxicities. Intraperitoneal cisplatin has a 10-20 fold increased 
peritoneal exposure compared to intravenous. (10) It has been argued that the high dose of 
100mg/m2 (as used in GOG-172) may not be necessary, as a dose reduction would still allow 
at least 10 times the concentration of systemic cisplatin to be delivered directly to the 
peritoneum. Reduced dose may result in reduced systemic toxicity. (33) However, it is also 
notable that all the positive studies (GOG-104, GOG-114 and GOG-172) used IP cisplatin at a 
dose of 100mg/m2, whereas the only adequately powered negative study (GOG252) used IP 
cisplatin at a dose of 75mg/m2. 
Carboplatin is equally as effective as cisplatin as an intravenous therapy, with reduced 
toxicities. (28) Intraperitoneal carboplatin has been investigated, but significantly less than 
cisplatin. This is likely due to early animal data, which demonstrated that 10 times the dose of 
intraperitoneal carboplatin was required for the equivalent dose of intraperitoneal cisplatin. 
(34) Retrospective analysis of patients treated with intraperitoneal cisplatin or carboplatin 
showed poorer response rates in those given carboplatin. (35) However, emerging retrospective 
data indicates around 400mg/m2 of intraperitoneal carboplatin is required for a survival benefit. 
This dose is considerably more than what was investigated in the previous negative trials (200-
300mg/m2), which may have resulted in falsely poor results. Intraperitoneal carboplatin is an 
effective, tolerable second line therapy in patient with minimal residual disease following 
intravenous cisplatin at a dose between 150-300mg/m2. (36, 37) This emerging evidence, along 
with the reduced neurotoxicity compared to a cisplatin paclitaxel combination, has led to 
increased interest in intraperitoneal carboplatin. (8) (38)  
Intraperitoneal paclitaxel is poorly absorbed into the peritoneum, resulting in cytotoxic 
concentrations for 24-48 hours following administration. (39) It can penetrate effectively 
through 80 cell layers. (8) Phase I and II trials found dosing of 60-75mg/m2 was effective and 
safe, with severe abdominal pain causing dose limiting toxicity. (8, 39, 40) (41) (42) Whether 
a taxane component should be given intra-peritoneal is debatable and could not be established 
in the Cochrane meta-analysis. (9)  
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Observational results of a new standardized protocol for intraperitoneal therapy in 69 patients 
with stage IIC-IV disease (residual <1cm) was reported. The protocol was; day 1 IV paclitaxel 
135mg/m2, day 2 IP cisplatin 75mg/m2, day 8 IP paclitaxel 60mg/m2, three-weekly for six 
cycles. (43) It included a standardised list of supportive medications, such as routine use of 
GCSF. Overall, patients received a greater number of intraperitoneal cycles compared to GOG-
172 (4.28 versus 3.66, p = 0.0088). There was a decreased rate of adverse events, including 
reduced neutropenia (48% versus 76%) and infection (5% versus 16%). The effect on survival 
was not analysed. (43) Furthermore, an outpatient-based regimen with a lower dose of cisplatin 
has been suggested: IV paclitaxel (135 mg/m2) over 3 hours on day 1, IP cisplatin (75 mg/m2) 
on day 2, and IP paclitaxel (60 mg/m2) on day 8, given every 21 days for 6 cycles. Median PFS 
was 29 months and overall survival 67 months, which was similar to GOG-172. A higher 
proportion completed treatment (80% completing 4 of more cycles, 56% completing all 6 
cycles).  (44) Both these observational studies suggest alterations in dosing and setting may 
still have potential survival benefits, whilst improving tolerability, although a randomised 
study would be required to demonstrate this.  
The optimum number of cycles is controversial. Analysis of 367 patients with stage III ovarian 
cancer followed up for 7 years suggested at least 5 cycles were needed for a survival advantage. 
(45) Longer term survival was analysed using participants from GOG-114 and GOG-172, with 
median follow up of 10.7 years. Median survival was prolonged in the intraperitoneal group 
(61.8 years versus 51.4 months). The risk of death was decreased by 12% for each cycle of 
intraperitoneal chemotherapy completed (AHR 0.88 95% CI 0.83-0.94 p<0.001). (46) 
Conversely, another analysis of 201 patients observed over 6 years illustrated no survival 
difference at 5 years between patients who received 1 to 2, 3 to 4, 5 to 6 cycles of intraperitoneal 
chemotherapy. (47) Overall, completion of intraperitoneal cycles appears to have pronounced 
effects, especially on long term outcome, and therefore ways to improve tolerability are 
paramount.  
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Cost Effectiveness:  
In 2007, Bristow et al. performed a cost-effectiveness analysis comparing intraperitoneal 
cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel, utilising GOG-172 and 
GOG-158 data. Intraperitoneal chemotherapy had an overall high cost of $39,861 per patient 
with an effectiveness of 5.16 QALYs. In comparison, intravenous therapy was $18,822 per 
patient with 4.59 QALYs. Inpatient treatment accounted for 43.2% of intraperitoneal 
chemotherapy cost, due to inpatient administration and toxicity related hospitalization. Though 
intraperitoneal therapy was cost-effective, minimising administration costs would benefit 
overall treatment value.(48)  
Havrilesky et al. 2008 similarly used the GOG-172 and GOG-158 data to assess cost 
effectiveness. Utilising a different model, they included costs for treatment and supportive care, 
and compared cost effectiveness of intravenous versus intraperitoneal therapy at 7, 11.5 and 35 
year horizons. Analysis included intravenous carboplatin/paclitaxel, intravenous 
cisplatin/paclitaxel and intraperitoneal cisplatin/paclitaxel. The incremental cost effectiveness 
ratio (ICER) was estimated at around $180,022 at the 7 year horizon, significantly more than 
Bristow et al. prediction (ICER $37,454). (49) (48) 
This discrepancy is likely due to; utilising different models with trial data at 6 month intervals, 
using mean survival time (as opposed to median) and estimating costings on intended as 
opposed to completed treatments. Similarly to Bristow, Havrilesky attributed the majority of 
cost to inpatient administration. Intraperitoneal cisplatin/paclitaxel administered as an 
outpatient would have favourable ICER to equivalent intravenous therapy. This relies on 
assumption that a shorter administration of intraperitoneal paclitaxel is equally as effective. 
Intraperitoneal treatment became more cost effective when a longer time horizon was 
modelled, providing the survival benefit persists. (49)  
Both studies highlight intraperitoneal chemotherapy is expensive. Any attempts to reduce costs 
via using outpatient administration and reduce toxicity related hospitalization are key.   
 
 
 
Subtypes:  
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Identifying patient who are more likely to have a good response to intraperitoneal 
chemotherapy would allow a tailored treatment approach. Those with low volume residual 
disease are more likely to respond to intraperitoneal chemotherapy as described. (13) Previous 
colonic resection has been associated with treatment non-completion due to complications and 
is a relative contra-indication. (1) (9) (45) Upper abdominal tumour metastasis was also 
associated with increased likelihood of discontinuing treatment. (45) The prognosis in elderly 
patients with clear cell tumours is poor and toxicities from intraperitoneal therapy are likely to 
exceed potential benefit according to Cochrane review. (45) (9) 
BRCA1 status, by immunohistochemistry, was examined in GOG-172 participants. 
Deleterious BRCA1 gene mutations whether derived from the germline or somatically acquired 
result in loss of protein expression. Previous data suggests reduced BRCA1 expression is 
associated with platinum hypersensitivity.(50) Of the 393 patients analysed, 189 patients had 
reduced or absent BRCA1 expression and 204 had normal expression. Interestingly, in those 
with abnormal BRCA1 expression the overall survival was significantly increased in the 
intraperitoneal group, versus intravenous group (84 versus 47 months, p = 0.0002). Abnormal 
BRCA expression was an independent prognostic factor for improved survival in the 
intraperitoneal group (HR 0.67 [0.47- 0.97], p = 0.032). In those with normal BRCA1 
expression, survival was similar when comparing intravenous versus intraperitoneal therapy. 
(51) These findings raise the possibility that patients with deleterious BRCA1 mutations, which 
are known to confer increased platinum sensitivity, particularly benefit from the increased dose 
intensity resulting from the intraperitoneal route of administration. 
Polymorphisms in the excision repair cross complementation group 1 (ERCC1) were 
investigated using GOG-172 data. The C8092A polymorphism was identified as a predictor of 
survival. Unfortunately, numbers were insufficient to make accurate conclusions to whether 
administration route influenced this, though this association was more pronounced in the 
intraperitoneal treatment arm. (52)  
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Uptake of intraperitoneal chemotherapy:  
Despite the described trials and the NCI alert, the uptake of intraperitoneal chemotherapy has 
been poor. The clinical use of intraperitoneal therapy was analysed using a prospective cohort 
study of over 800 woman with stage III debulked ovarian tumours from 6 National 
Comprehensive Cancer Network Institutes between 2006 and 2012. Intraperitoneal 
chemotherapy use increased from 0% to 33% between 2003 and 2006, and then increased 
further to 50% in 2007/2008. There was no change thereafter. Intraperitoneal chemotherapy 
resulted in a significantly improved overall survival (81% v 71% at 3 years; HR 0.68; 95% CI: 
0.47 to 0.99), compared with intravenous chemotherapy, but with an increased rate of 
discontinuation or change of route. (53)  
In 2010, surveys were sent to all members of the Society of Gynaecology Oncologists (SGO) 
and 200 members of American Society of Clinical Oncology (ASCO). They received 209 
responses, 24% of SGO and 3% of ASCO. The majority offered intraperitoneal chemotherapy 
(77%), often 75mg/m2 cisplatin. Given the likely bias in those completing the survey, the 
authors concluded the use of intraperitoneal therapy was low. (54)  
The general consensus is that Europe has even poorer uptake of intraperitoneal chemotherapy 
than the United States though no studies comparing this were identified. (46) Recent National 
Institute of Clinical Excellence (NICE) guidelines in the United Kingdom in 2011 state that 
intraperitoneal chemotherapy should not be offered to patients outwith a clinical trial setting. 
(55) Review articles, written by oncologists based on Italy and based in Germany, also did not 
support its routine use. (56) (57)  
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Conclusions:  
Intraperitoneal chemotherapy remains an enigma. Adequately powered phase III studies that 
used cisplatin at a dose of 100mg/m2 were largely positive and one of these (GOG-172) 
demonstrated a 16-month improvement in overall survival which is amongst the most 
impressive results ever seen in ovarian cancer first line trials. However, many of these trials 
can be criticised for not comparing equivalent chemotherapy dose intensities in the IP and IV 
arms. In addition, the IP arms of the largest studies were often less tolerable (most notably in 
GOG172). A suitable and effective dose of IP carboplatin has not yet been identified, although 
the regime used in the OV21/PETROC study was equally tolerable to the IV arm and there was 
a suggestion of activity for this regime. 
Current priority areas for first line clinical trials are focussed around novel therapies such as 
PARP inhibitors, antiangiogenics, immune checkpoint inhibitors and combinations of these 
agents. As such, there is little appetite at present for academic studies of cytotoxic route of 
delivery or scheduling. However, the possibility remains that a major opportunity for 
improving outcome is being missed. The basic immunohistological analysis suggesting 
patients in GOG-172 who had loss of BRCA1 protein particularly benefited from IP 
chemotherapy makes biological sense because loss of BRCA1, BRCA2 or other proteins 
involved in homologous recombination repair is known to confer platinum sensitivity. It is very 
possible that it is exactly these patients who benefit from the increased exposure to platinum 
achieved by the IP route of administration. Gene sequence analysis on retrospective material 
from previous IP studies or prospective recruitment into randomised IP studies based upon loss 
of homologous recombination repair genes is required in order to more fully explore this 
possibility.  
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